News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 205–216 of 243 stories

Fios Genomics Engaged by Niki BioSolutions for Alzheimer's Programme Analysis

Fios Genomics has been engaged by Niki BioSolutions' subsidiary DiamiR Biosciences to provide bioinformatics and biostatistical analysis in support of Niki's Alzheimer's disease testing programme. Fios will analyse and interpret multi-omics data generated across the programme to help sharpen target and biomarker decisions as Niki advances its Alzheimer's assays through development.

Funding & Grants14 Sept 2026

Dimension Biotechnologies Launches with £700k to Develop Microvascular Disease Blood Test

Dimension Biotechnologies has launched out of the University of Bristol with more than £700,000 in pre-seed funding to develop a blood test for microvascular disease. The platform measures changes in the glycocalyx, the sugar-rich lining of blood vessels, to give an early biochemical readout of vascular damage linked to kidney disease, cardiovascular disease and dementia, without imaging or tissue biopsies. The round combines £490,000 from Kidney Research UK, the University of Bristol, angel investors and the KQ Labs Accelerator, plus £215,000 in Innovate UK grant funding.

Funding & Grants10 Sept 2026

Transition Bio Wins $750k Little Warrior Foundation Grant for Ewing Sarcoma

Transition Bio has received a $750,000 grant from the Little Warrior Foundation to pursue a therapy against EWS-FLI1, the fusion protein that drives Ewing sarcoma. The company will apply its microfluidics and machine learning platform for intrinsically disordered proteins to characterise EWS-FLI1 and design small molecules that disrupt it, targeting what would be the first precision treatment for the disease.

NodThera Renames as Rezera and Plans Phase 3 Trial of Ruvonoflast in Peripheral Artery Disease

NodThera has changed its name to Rezera and plans to start a Phase 3 registrational trial of its lead NLRP3 inhibitor, ruvonoflast, in peripheral artery disease in the first half of 2027. The company has reached regulatory alignment on the core elements of the trial, following completion of its Phase 2 RESOLVE-1 and RESOLVE-2 studies. Rezera, headquartered in Boston with its R&D base in Cambridge, UK, has also strengthened its leadership team, appointing Geoff McDonough as Chief Executive Officer.

IMU Biosciences Licenses HD Immunology Platform to Eurofins Transplant Genomics

IMU Biosciences has signed a licensing agreement giving Eurofins Transplant Genomics exclusive access to its High Definition Immunology platform for transplant-related clinical development programmes. The deal puts IMU's high-throughput immune profiling into one of the largest post-transplant monitoring networks, targeting suboptimal immunosuppression as a driver of chronic rejection and premature graft loss.

Funding & Grants9 Sept 2026

ViaNautis Adds SCI Ventures as Investor, Expands into Spinal Cord Injury

ViaNautis has taken investment from SCI Ventures, a specialist fund backed by clinical centres and research foundations working on paralysis, adding chronic spinal cord injury to its CNS portfolio. The programme applies polyNaut, the company's nanobody-guided polymer nanovesicle platform, to deliver regenerative genetic payloads to cells at and around spinal cord lesions, an indication with no approved regenerative therapies to date.

Cytospire Therapeutics Appoints Sumeet Ambarkhane as Chief Medical Officer

Cytospire Therapeutics has appointed Sumeet Ambarkhane as Chief Medical Officer. Ambarkhane, previously CMO at Pathios Therapeutics and Alligator Bioscience, will lead clinical development of CYT X300, Cytospire's lead pan-gamma delta T cell engager for EGFR-positive solid tumours, as the programme moves towards first-in-human studies.

Holiferm Combines with Organica UK to Build End-to-End Biosurfactant Business

Holiferm has announced a strategic combination with Organica UK, pairing its fermentation-derived biosurfactants with Organica's biodegradable household and cleaning product formulation and manufacturing. Backed by a continued partnership with investor Sadorp, the combined business spans ingredient development through to finished products, with the two companies continuing to operate from adjacent sites in the North West.

Brainomix e-Lung Detects Treatment Effects in Endeavor's Phase 2a IPF Trial

Brainomix and Endeavor BioMedicines have presented results from an AI-driven quantitative analysis of HRCT imaging in Endeavor's Phase 2a trial of taladegib for idiopathic pulmonary fibrosis, at the European Respiratory Society Congress in Barcelona. The post-hoc analysis using Brainomix 360 e-Lung found significant differences favouring taladegib in lung volume, overall interstitial lung disease burden and total fibrosis extent, and the companies plan to extend the collaboration into further trials.

Genflow Meets Primary Endpoint in SLAB Longevity Gene Therapy Trial

Genflow Biosciences' SLAB clinical trial, evaluating its SIRT6 centenarian gene therapy in 24 aged beagle dogs, has met its primary endpoint of reduced biological age as measured by the GRIM methylation clock. Treated animals showed a clear improvement over saline controls across naked DNA and AAV8 dosing arms, building on earlier positive interim data from February and April 2026. Detailed results, including muscle histology data, will be presented at the Animal Longevity Summit in Toronto on 1-2 October 2026, as the company continues discussions with animal health companies on potential licensing and co-development.